tbuckley/cabot-search huggingface dataset:
COVID‐19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations
Authors: Marek Jutel, Maria J. Torres, Oscar Palomares, Cezmi A. Akdis, Thomas Eiwegger, Eva Untersmayr, Domingo Barber, Magdalena Zemelka‐Wiacek, Anna Kosowska, Elizabeth Palmer, Stefan Vieths, Vera Mahler, Walter G. Canonica, Kari Nadeau, Mohamed H Shamji, Ioana Agache
Journal: Allergy (2022)

Abstract Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen‐specific manner via allergen immunotherapy (AIT) or in an endotype‐driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)‐5 and IL‐4/IL‐13 or non‐type 2 response: anti‐cytokine antibodies and B‐cell depletion via anti‐CD20. Coronavirus disease 2019 (COVID‐19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS‐CoV‐2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID‐19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID‐19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID‐19 infection, of COVID‐19 vaccine, of AIT and of biologicals and considered the data published for other anti‐infectious vaccines administered concurrently with AIT or biologicals.
Public Health Consequences Among First Responders to Emergency Events Associated With Illicit Methamphetamine Laboratories—Selected States, 1996-1999
Journal: JAMA (2000)

Methamphetamine, a central nervous system stimulant, is manufactured in illicit laboratories using over-the-counter ingredients. Many of these ingredients are hazardous substances that when released from active or abandoned methamphetamine laboratories can place first responders at risk for serious injuries and death. In 16 states, the Agency for Toxic Substances and Disease Registry maintains the Hazardous Substances Emergency Events Surveillance (HSEES) system to collect and analyze data about the morbidity and mortality associated with hazardous substance-release events. Based on events reported to HSEES during 1996-1999, this report describes examples of events associated with illicit methamphetamine laboratories that resulted in injuries to first responders in three states, summarizes methamphetamine-laboratory events involving injured first responders, and suggests injury prevention methods to protect first responders.
Association of BNT162b2 COVID-19 Vaccination During Pregnancy With Neonatal and Early Infant Outcomes
Authors: Inbal Goldshtein, David M. Steinberg, Jacob Kuint, Gabriel Chodick, Yaakov Segal, Shirley Shapiro Ben David, Amir Ben-Tov
Journal: JAMA Pediatrics (2022)

Pregnant women were excluded from the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine (Pfizer-BioNTech) preauthorization trial. Therefore, observational data on vaccine safety for prenatally exposed newborns are critical to inform recommendations on maternal immunization.To examine whether BNT162b2 mRNA vaccination during pregnancy is associated with adverse neonatal and early infant outcomes among the newborns.Population-based cohort study comprising all singleton live births in March through September 2021, within a large state-mandated health care organization in Israel, followed up until October 31, 2021.Maternal BNT162b2 mRNA vaccination during pregnancy.Risk ratios (RR) of preterm birth, small birth weight for gestational age (SGA), congenital malformations, all-cause hospitalizations, and infant death. Stabilized inverse probability weighting was used to adjust for maternal age, timing of conception, parity, socioeconomic status, population subgroup, and maternal influenza immunization status.The cohort included 24 288 eligible newborns (49% female, 96% born at ≥37 weeks' gestation), of whom 16 697 were exposed (n = 2134 and n = 9364 in the first and second trimesters, respectively) to maternal vaccination in utero. Median (IQR) follow-up after birth was 126 days (76-179) among exposed and 152 days (88-209) among unexposed newborns. No substantial differences were observed in preterm birth rates between exposed and unexposed newborns (RR = 0.95; 95% CI, 0.83-1.10) or SGA (RR = 0.97; 95% CI, 0.87-1.08). No significant differences were observed in the incidence of all-cause neonatal hospitalizations (RR = 0.99; 95% CI, 0.88-1.12), postneonatal hospitalizations after birth (RR = 0.95; 95% CI, 0.84-1.07), congenital anomalies (RR = 0.69; 95% CI, 0.44-1.04), or infant mortality over the study period (RR = 0.84; 95% CI, 0.43-1.72).This large population-based study found no evident differences between newborns of women who received BNT162b2 mRNA vaccination during pregnancy, vs those of women who were not vaccinated, and contributes to current evidence in establishing the safety of prenatal vaccine exposure to the newborns. Interpretation of study findings is limited by the observational design.
Another tobacco report proposed
Authors: C. Marwick
Journal: JAMA (1988)

BURIED in massive federal tax law corrections are five paragraphs requesting the surgeon general of the Public Health Service to study the health care costs of smoking. Put into the House bill by Representative Michael A. Andrews (D, Texas), the legislation calls for a report to be sent to Congress every two years. The study would also compare smokers with those passively exposed to tobacco and with nonsmokers and would survey incidence of smoking in the United States. The House passed its version of the tax revision bill in August. A similar bill has yet to be acted upon by the Senate. The legislation has been opposed by a number of senators from tobacco-growing states. But this opposition is not the central problem. There are significant differences between the two bills in terms of the tax revisions they contain. These could slow passage of the Senate bill, particularly as there
The social significance of the danger list
Authors: A. D. Weisman
Journal: JAMA (1971)

A survey of how the concept of the "Danger List" is used disclosed that only a minority of danger list (DL) patients die in the hospital, that medical care is not significantly influenced by the DL, and that autopsy permission is granted more frequently when a patient who dies is not on the DL. Despite its obsolescence and replacement by more efficient methods of informing families of a patient's condition the DL should be revised with high-risk families of critically ill patients in mind. Early psychosocial intervention by social workers or nurse-clinicians in collaboration with the responsible physician will not only assist families in solving practical problems related to death and social transition, but may help prevent later complications in the bereavement period.
Meniscectomies in women
Authors: J. A. Powers
Journal: JAMA (1969)

During the past years a number of arthrotomies in women have been done with the presumptive diagnosis of a tear of the meniscus. In a disproportionately large number, the preoperative diagnosis was not confirmed and no tear of the meniscus could be identified. Even in the hands of experienced, responsible orthopedic surgeons, the diagnosis of meniscal tear in a woman is often incorrect. There are several reasons for this and many other pathologic factors that might give rise to the symptoms simulating meniscal tear are involved.
12. New Treatments
Authors: Z Nagy, S Leyer, D Vlock, J Gutheil, D Gold, J Bender, S Rosenbusch, J Barton, K Hamblett, C Cerveny, J Andreyka, K Kissler, I Stone, M Sun, P Senter, A Wahl, J Francisco, N Ihle
Journal: Annals of Oncology (2005)
Multiscale temporal integration organizes hierarchical computation in human auditory cortex
Authors: Sam V. Norman-Haignere, Laura K. Long, Orrin Devinsky, Werner Doyle, Ifeoma Irobunda, Edward M. Merricks, Neil A. Feldstein, Guy M. McKhann, Catherine A. Schevon, Adeen Flinker, Nima Mesgarani
Journal: Nature Human Behaviour (2022)
Attention-deficit/hyperactivity disorder
Authors: Stephen V. Faraone, Philip Asherson, Tobias Banaschewski, Joseph Biederman, Jan K. Buitelaar, Josep Antoni Ramos-Quiroga, Luis Augusto Rohde, Edmund J. S. Sonuga-Barke, Rosemary Tannock, Barbara Franke
Journal: Nature Reviews Disease Primers (2015)
Bipolar disorders
Authors: Roger S McIntyre, Michael Berk, Elisa Brietzke, Benjamin I Goldstein, Carlos López-Jaramillo, Lars Vedel Kessing, Gin S Malhi, Andrew A Nierenberg, Joshua D Rosenblat, Amna Majeed, Eduard Vieta, Maj Vinberg, Allan H Young, Rodrigo B Mansur
Journal: The Lancet (2020)
Re: Jana S. Hopstaken, Joyce G.R. Bomers, Michiel J.P. Sedelaar, et al. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol 2022;81:5–33
Authors: Francesco Montorsi, Armando Stabile, Giorgio Gandaglia, Alberto Briganti
Journal: European Urology (2022)
Cardiovascular Pharmacogenomics
Authors: Dan M. Roden, Julie A. Johnson, Stephen E. Kimmel, Ronald M. Krauss, Marisa Wong Medina, Alan Shuldiner, Russell A. Wilke
Journal: Circulation Research (2011)

Patients vary in their responses to drug therapy, and some of that variability is genetically determined. This review outlines general approaches used to identify genetic variation that influences drug response. Examples from specific therapeutic areas are presented, such as cholesterol management, arrhythmias, heart failure, hypertension, warfarin anticoagulation, and antiplatelet agents. A brief view of potential pathways to implementation is presented.
ST. LUKE'S HOSPITAL OF NEW YORK.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Letter to the Editor
Authors: Siri Lillegraven, Nina Sundlisaeter, Espen Haavardsholm
Journal: JAMA (2021)

In ReplyIn response to our study on tapering of csDMARDs in patients with RA in remission, 1 Dr Baker and colleagues discuss the potential for successful tapering, and even drug-free remission, in RA.They highlight that our study results can be interpreted differently than the main conclusion of the article, which was also discussed in the Editorial by Curtis et al. 2 Although the ARCTIC REWIND trial showed an almost 4-fold increase in flare rate for patients randomized to halfdose csDMARDs compared with stable-dose csDMARDs, the results also showed that 75% of patients receiving half-dose csDMARDs did not experience a flare after 1 year.Additionally, most patients with flares regained remission after reinstating full-dose csDMARD treatment.However, studies indicate that even manageable flares and fluctuations in disease activity can affect the daily lives of patients, yielding reminders of the unpredictability of RA. 3,4 Baker and colleagues suggest that successful tapering can be possible within subgroups of patients, eg, based on serologic status or achievement of rigorous remission criteria such as the ACR/EULAR Boolean remission. 5,6 Analyses of the primary end point of the ARCTIC REWIND csDMARD study revealed no statistically significant difference in flare rate based on serologic status in patients receiving half-dose therapy: 24% (16/67) among seropositive patients vs 30% (3/10) among seronegative patients (P = .70).Additionally, 22% (11/50) of patients in remission, as defined by ACR/EULAR Boolean criteria, experienced a flare compared with 30% (8/27) of patients not fulfilling these criteria at baseline (P = .58).We also assessed baseline predictors for successful tapering in the 77 patients randomized to half-dose csDMARDs who were treated per protocol.During the 1-year follow-up, 25% (19 patients) experienced a flare.The final multivariate model shows anticitrullinated protein antibody level (range, 0-340 IU/mL; odds ratio, 1.05 [95% CI, 1.00-1.09]per 10 units; P = .03)and Disease Activity Score (odds ratio, 6.43 [95% CI, 1.07-38.84];P = .04)at time of tapering to be associated with a subsequent disease flare, although the cross-validated area under the curve for the model was low (0.55 [95% CI,).The results of subgroup analyses and predictor analyses indicate there still is an unmet need for risk stratification variables that can successfully guide personalized tapering of treatment in RA.The ARCTIC REWIND data can inform shared decisionmaking, which takes into account the consequences of a potential flare for an individual patient and the benefits of drug reduction.In a second phase of the current study, patients with RA who maintained remission for a year after tapering csDMARD to a half dose were randomized to either continued half-dose treatment or withdrawal of csDMARD.These data will add to the understanding of whether drugfree remission can be achievable for patients with RA.
Public Health and Private Practice
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Proceedings of a symposium on crystal-related arthropathies. 22 October and 23 October, 1982, Bristol Polytechnic, Bristol.
Journal: Annals of the Rheumatic Diseases (1983)

Monosodium urate monohydrate Urate spherulites Ultrasmall urate crystals Monoclinic calcium pyrophosphate dihydrate Triclinic calcium pyrophosphate dihydrate Ultrasmall pyrophosphate crystals Hydroxyapatite Carbonate apatite Octacalcium phosphate Apatite spherulites Dicalcium phosphate dihydrate Calcium triphosphate Calcium carbonate Calcium oxalate Cholesterol Liquid lipid crystals Mixtures of crystals have been identified in human articular tissue.Faced with such a list and appreciating the wide range of different techniques used for tissue sampling, particle extraction, and crystal identification, the sensitivity and selectivity of the methods used must be established.Errors and artefacts are easily introduced by the methods, and it is easier to find a particle than to say either what it is or when it appeared and where it came from.copyright.
Therapeutic talk
Authors: J. P. Callan
Journal: JAMA (1980)

A decade ago during the Vietnam conflict, the initials "R&amp;R," like many other abbreviations and flip phrases of those troubled years, came into common parlance. This is an abbreviation for "rest and relaxation," a period of recuperation and making love far from the daily grind of making war. Today, as then and centuries ago, physicians are charged with the responsibility of establishing for their patients another kind of R&amp;R, in a different war. Their battle is the eternal campaign against sickness, pain, and discomfort, and their objective can be reached by mobilizing medicine's R&amp;R, reassurance and relief of suffering. The latest advances in pharmaceutical progress may be used to achieve that goal, but it can be reached with another type of medicine, one that is sometimes doubted by patient and practitioner alike. This discounted treatment is talk; a patient-physician exchange, which, when used with the same gusto as pharmaceuticals, can
Liver transplantation: Viral hepatitis
Journal: Hepatology (1995)

Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and for patients with liver cell cancer related to liver disease.Acute and chronic liver diseases related to hepatitis viruses are between the main indications for liver transplantation.The risk of viral reinfection after transplantation is the main limiting factor in these indications.Before the availability of antiviral prophylaxis, hepatitis B virus (HBV) recurrence was universal in patients who were HBV DNA-positive before transplantation.The natural history of recurrent HBV was accelerated by immunosuppression, and it progressed rapidly to graft failure and death.Introduction of post-transplant prophylaxis with immunoglobulin alone first, and associated to antiviral drugs later, drastically reduced HBV recurrence, resulting in excellent long-term outcomes.On the contrary, recurrence of hepatitis C is the main cause of graft loss in most transplant programs.Overall, patient and graft survival after LT for hepatitis C virus (HCV)-associated cirrhosis is inferior compared with other indications.However, successful pretransplant or post transplant antiviral therapy has been associated with increased graft and overall survival.Until recently, the combination of pegylated interferon and ribavirin was the standard of care for the treatment of patients with chronic hepatitis C. Highly active antiviral compounds have been developed over the past decade, thanks to new in vitro systems to study HCV entry, replication, assembly, and release.
Dermatology Academy Drafts Skin Cancer Warning
Authors: Charles Marwick
Journal: JAMA (1992)

MOUNTING EVIDENCE that occupational and recreational exposure, as well as other human-contrived hazards, are major contributors to skin cancers is prompting the American Academy of Dermatology to call for a national action plan. During a two-day conference in Washington, DC, the academy drafted a statement warning of increasing environmental hazards to the skin, especially those resulting in malignant melanoma. The statement is to be considered for approval by the academy's Board of Directors early this month. <h3>Cancer Alert Projects</h3> Projects drawing attention to the increasing risk of skin cancers are also being planned, says an academy spokesman, although he said he could not be specific because they have not yet been approved. But, he says: "There is a concern that this meeting be followed up with some substantative projects." Skin carcinomas are the most common cancers in the United States, with about 600 000 new cases reported annually. Basal and
Foreword
Journal: JNCI Journal of the National Cancer Institute (1972)

Foreword Get access Ernest L. Wynder, M.D. Ernest L. Wynder, M.D. Workshop Chairman and Editor Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 48, Issue 6, June 1972, Page 1741, https://doi.org/10.1093/jnci/48.6.1741 Published: 01 June 1972
Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer
Authors: Yi Wang, Yuya Wang, Yifei Ren, Qi Zhang, Ping Yi, Chunming Cheng
Journal: Seminars in Cancer Biology (2022)

Cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4) or programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)–based immune checkpoint inhibitors (ICIs) have led to significant improvements in the overall survival of patients with certain cancers and are expected to benefit patients by achieving complete, long-lasting remissions and cure. However, some patients who receive ICIs either fail treatment or eventually develop immunotherapy resistance. The existence of such patients necessitates a deeper understanding of cancer progression, specifically nutrient regulation in the tumor microenvironment (TME), which includes both metabolic cross-talk between metabolites and tumor cells, and intracellular metabolism in immune and cancer cells. Here we review the features and behaviors of the TME and discuss the recently identified major immune checkpoints. We comprehensively and systematically summarize the metabolic modulation of tumor immunity and immune checkpoints in the TME, including glycolysis, amino acid metabolism, lipid metabolism, and other metabolic pathways, and further discuss the potential metabolism-based therapeutic strategies tested in preclinical and clinical settings. These findings will help to determine the existence of a link or crosstalk between tumor metabolism and immunotherapy, which will provide an important insight into cancer treatment and cancer research.
Scleromalacia Perforans: Fascia Lata or Scleral Grafting
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal